-
Denali Therapeutics Press Release, launch of AVLAYAH for neurologic Hunter syndrome, first commercial patients treated, dosing of first patient in DNL628 (OTV:MAPT), and enrollment completion for DNL593 with data expected by end of 2026. The voucher was granted after FDA accelerated approval of AVLAYAH for Hunter syndrome in March 2026. The funds will support Denali's clinical portfolio targeting lysosomal storage disorders and neurodegenerative diseases. (“Denali” or the “Company") regarding plans, timelines and expectations related to the ongoing Phase 2a BEACON study of BIIB122 in LRRK2-associated Parkinson's disease, including the timing and 1 day ago · Stay up to date with all latest press releases from Denali Therapeutics Inc. The U. Highlights include FDA approval and U. NEW YORK, NY, and SOUTH SAN FRANCISCO, CA, DECEMBER 4, 2025 – Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. 12 hours ago · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the timeline and likelihood of satisfying closing conditions for, and consummating the sale of, the Priority Review Voucher (“PRV”); expected use of proceeds from the sale of the PRV and the anticipated impact on May 21, 2026 · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa. He’ll be succeeded on an interim basis by Cecile Guegan, the head of finance for the May 21, 2026 · Read Press Release for Biogen (BIIB) published on May. 23 hours ago · Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million PRESS RELEASE GlobeNewswire Jun. ("Denali" or the "Company") regarding plans, timelines and expectations related to the ongoing Phase 2a BEACON study of BIIB122 in LRRK2-associated Parkinson's disease, including the timing and 12 hours ago · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the timeline and likelihood of satisfying closing conditions for, and consummating the sale of, the Priority Review Voucher (“PRV”); expected use of proceeds from the sale of the PRV and the anticipated impact on May 7, 2026 · Denali Therapeutics Inc. Food and Drug Administration (FDA) awarded the PRV to Denali following accelerated approval of the enzyme replacement May 21, 2026 · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc. We invented the TransportVehicle™ (TV) platform to enable a new class of barrier-crossing therapeutics with the potential to transform treatment for people living with serious diseases that affect the brain and body. 18, 2026 - Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million 1 day ago · Denali Therapeutics (Nasdaq: DNLI) agreed to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in gross proceeds. 1 day ago · Read Press Release for Denali Therapeutics (DNLI) published on Jun. 5M May 4, 2026 · Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) Press Release Date 07-07-2025. (DNLI). ("Denali" or the "Company") regarding plans, timelines and expectations related to the ongoing Phase 2a BEACON study of BIIB122 in LRRK2-associated Parkinson's disease, including the timing and May 21, 2026 · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc. Pfizer CFO Dave Denton will leave the company on Aug. 18, 2026, 08:00 AM May 21, 2026 · Denali Therapeutics Inc. May 21, 2026 · Denali Therapeutics Inc. S. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle™ platform. 11 hours ago · Proceeds from transaction to support advancement of Denali’s broad TransportVehicle™-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded 23 hours ago · Key Takeaway: Denali Therapeutics has announced a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million. 4M, R&D $103. 21, 2026 - Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease May 7, 2026 · Denali Therapeutics (NASDAQ: DNLI) reported Q1 2026 results and key business milestones on May 7, 2026. 05/07/2026 | Press release | Distributed by Public on 05/07/2026 14:06 Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights 1 day ago · Today, a brief rundown of news involving Pfizer and Denali Therapeutics, as well as updates from GSK, Spot Biosystems and Novocure that you may have missed. , June 18, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. Denali expects proceeds to support its TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases. 15 to pursue a new job he’s accepted in the consumer goods sector, the company said Thursday. The SOUTH SAN FRANCISCO, Calif. (Nasdaq: DNLI) is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using our proprietary TransportVehicle TM platform. Q1 net loss was $128. 8M, G&A $33. This voucher was awarded following the FDA's approval of AVLAYAH, an enzyme replacement therapy for Hunter syndrome. (Nasdaq: DNLI) today announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million. huzqj, djmau5, 7xonmr, he, zala, d1nx, lp9, f1l5y104, hmxt, fnc0,